SI2809349T1 - Imunogeni sestavek - Google Patents
Imunogeni sestavekInfo
- Publication number
- SI2809349T1 SI2809349T1 SI201331329T SI201331329T SI2809349T1 SI 2809349 T1 SI2809349 T1 SI 2809349T1 SI 201331329 T SI201331329 T SI 201331329T SI 201331329 T SI201331329 T SI 201331329T SI 2809349 T1 SI2809349 T1 SI 2809349T1
- Authority
- SI
- Slovenia
- Prior art keywords
- immunogenic composition
- immunogenic
- composition
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN281MU2012 | 2012-01-30 | ||
| EP13743463.5A EP2809349B1 (en) | 2012-01-30 | 2013-01-29 | Immunogenic composition |
| PCT/IB2013/050739 WO2013114268A1 (en) | 2012-01-30 | 2013-01-29 | Immunogenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2809349T1 true SI2809349T1 (sl) | 2019-03-29 |
Family
ID=54259032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201331329T SI2809349T1 (sl) | 2012-01-30 | 2013-01-29 | Imunogeni sestavek |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9198977B2 (enExample) |
| EP (1) | EP2809349B1 (enExample) |
| JP (1) | JP6042455B2 (enExample) |
| KR (1) | KR101897317B1 (enExample) |
| CN (1) | CN104302315B (enExample) |
| BR (1) | BR112014018815B1 (enExample) |
| CA (1) | CA2863178C (enExample) |
| DK (1) | DK2809349T3 (enExample) |
| ES (1) | ES2707294T3 (enExample) |
| HU (1) | HUE040914T4 (enExample) |
| MX (1) | MX354103B (enExample) |
| PT (1) | PT2809349T (enExample) |
| RU (1) | RU2634405C2 (enExample) |
| SG (1) | SG11201404447WA (enExample) |
| SI (1) | SI2809349T1 (enExample) |
| TR (1) | TR201900778T4 (enExample) |
| WO (1) | WO2013114268A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2878307T3 (pl) | 2005-06-27 | 2020-01-31 | Glaxosmithkline Biologicals S.A. | Kompozycja immunogenna |
| CN104936615B (zh) * | 2012-11-21 | 2017-03-29 | 印度血清研究所私人有限公司 | 高产量的细菌多糖的制备 |
| WO2015029056A1 (en) | 2013-08-24 | 2015-03-05 | Bharat Biotech International Limited | A bacterial vaccine and methods for manufacture thereof |
| EP2921856B1 (en) | 2014-03-18 | 2016-09-14 | Serum Institute Of India Private Limited | A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines |
| MX2017015985A (es) * | 2015-06-08 | 2018-08-15 | Serum Inst Of India Private Ltd | Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y formulacion de vacuna multivalente obtenida con los mismos. |
| AU2016290233A1 (en) * | 2015-07-04 | 2018-01-25 | Bharat Biotech International Limited | Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides |
| BR112018068523A2 (pt) * | 2016-03-15 | 2019-01-22 | Msd Wellcome Trust Hilleman Laboratories Pvt Ltd | novos conjugados de polissacarídeo-proteína e processo para obter os mesmos |
| CN106110316A (zh) * | 2016-06-27 | 2016-11-16 | 北京智飞绿竹生物制药有限公司 | 一种肺炎球菌结合物组合疫苗的制备方法 |
| KR20190044663A (ko) | 2016-09-02 | 2019-04-30 | 사노피 파스퇴르 인크 | 네이세리아 메닌기티디스 백신 |
| CN106397537B (zh) * | 2016-10-13 | 2020-01-07 | 李红臣 | 一种高效快速的多糖蛋白结合疫苗纯化分析方法 |
| AU2018262438B2 (en) * | 2017-05-05 | 2022-07-14 | Serum Institute Of India Private Limited | Method for removal of impurities from bacterial capsular polysaccharide based preparations |
| BR112019027182A2 (pt) * | 2017-06-27 | 2020-06-30 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | nova composição de vacina conjugada de proteína - polissacarídeo multivalente e formulação da mesma |
| US20200353064A1 (en) * | 2018-01-29 | 2020-11-12 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Novel meningococcal vaccine composition and process thereof |
| WO2019198096A1 (en) * | 2018-04-11 | 2019-10-17 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Tetravalent meningococcal vaccine composition and process to prepare thereof |
| JOP20200214A1 (ar) | 2019-09-03 | 2021-03-03 | Serum Institute Of India Pvt Ltd | تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها |
| CA3155669A1 (en) | 2019-09-27 | 2021-04-01 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| EP4192499A4 (en) | 2020-08-10 | 2024-09-25 | Inventprise, Inc. | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f |
| CN118078981A (zh) * | 2024-04-26 | 2024-05-28 | 成都康华生物制品股份有限公司 | 一种基于双蛋白载体的五价脑膜炎球菌多糖结合疫苗的制备方法及其产品 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2763244B1 (fr) * | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
| CZ20024224A3 (cs) * | 2000-06-29 | 2003-05-14 | Glaxosmithkline Biologicals S. A. | Farmaceutický prostředek |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| GB0130215D0 (en) * | 2001-12-18 | 2002-02-06 | Glaxosmithkline Biolog Sa | Vaccine |
| ATE506963T1 (de) * | 2003-10-02 | 2011-05-15 | Novartis Vaccines & Diagnostic | Kombinationsimpfstoffe gegen meningitis |
| PL2878307T3 (pl) * | 2005-06-27 | 2020-01-31 | Glaxosmithkline Biologicals S.A. | Kompozycja immunogenna |
| GB0513069D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| CN101287488B (zh) * | 2005-09-01 | 2013-01-30 | 诺华疫苗和诊断有限两合公司 | 含血清群c脑膜炎球菌的多价疫苗 |
| PL3017827T3 (pl) * | 2005-12-22 | 2019-04-30 | Glaxosmithkline Biologicals Sa | Szczepionka z koniugatem polisacharydu pneumokokowego |
| GB0703369D0 (en) * | 2007-02-21 | 2007-03-28 | Health Prot Agency | Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines |
| KR101635795B1 (ko) * | 2009-12-17 | 2016-07-04 | 피나 바이오솔루션스, 엘엘씨 | 다당류/단백질 접합체 백신의 제조에 있어서 시안화제인 1-시아노벤조트리아졸 (1-cbt)을 통한 다당류의 활성화 |
| AU2013265336A1 (en) * | 2012-05-22 | 2014-12-04 | Novartis Ag | Meningococcus serogroup X conjugate |
-
2013
- 2013-01-29 CA CA2863178A patent/CA2863178C/en active Active
- 2013-01-29 HU HUE13743463A patent/HUE040914T4/hu unknown
- 2013-01-29 SI SI201331329T patent/SI2809349T1/sl unknown
- 2013-01-29 WO PCT/IB2013/050739 patent/WO2013114268A1/en not_active Ceased
- 2013-01-29 SG SG11201404447WA patent/SG11201404447WA/en unknown
- 2013-01-29 DK DK13743463.5T patent/DK2809349T3/da active
- 2013-01-29 CN CN201380017781.9A patent/CN104302315B/zh active Active
- 2013-01-29 PT PT13743463T patent/PT2809349T/pt unknown
- 2013-01-29 KR KR1020147024348A patent/KR101897317B1/ko active Active
- 2013-01-29 ES ES13743463T patent/ES2707294T3/es active Active
- 2013-01-29 MX MX2014009250A patent/MX354103B/es active IP Right Grant
- 2013-01-29 BR BR112014018815-7A patent/BR112014018815B1/pt active IP Right Grant
- 2013-01-29 US US14/375,385 patent/US9198977B2/en active Active
- 2013-01-29 RU RU2014134288A patent/RU2634405C2/ru active
- 2013-01-29 JP JP2014555364A patent/JP6042455B2/ja active Active
- 2013-01-29 EP EP13743463.5A patent/EP2809349B1/en active Active
- 2013-01-29 TR TR2019/00778T patent/TR201900778T4/tr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6042455B2 (ja) | 2016-12-14 |
| CN104302315B (zh) | 2018-02-06 |
| BR112014018815A8 (pt) | 2017-07-11 |
| TR201900778T4 (tr) | 2019-02-21 |
| US9198977B2 (en) | 2015-12-01 |
| PT2809349T (pt) | 2019-02-01 |
| BR112014018815B1 (pt) | 2022-07-12 |
| MX354103B (es) | 2018-02-13 |
| MX2014009250A (es) | 2015-03-19 |
| HUE040914T4 (hu) | 2019-05-28 |
| EP2809349A1 (en) | 2014-12-10 |
| SG11201404447WA (en) | 2014-08-28 |
| EP2809349B1 (en) | 2018-12-19 |
| ES2707294T3 (es) | 2019-04-03 |
| CA2863178A1 (en) | 2013-08-08 |
| DK2809349T3 (da) | 2019-02-18 |
| RU2634405C2 (ru) | 2017-10-26 |
| CA2863178C (en) | 2021-04-06 |
| EP2809349A4 (en) | 2015-08-26 |
| WO2013114268A1 (en) | 2013-08-08 |
| KR20140123553A (ko) | 2014-10-22 |
| BR112014018815A2 (enExample) | 2017-06-20 |
| KR101897317B1 (ko) | 2018-09-11 |
| US20140377302A1 (en) | 2014-12-25 |
| RU2014134288A (ru) | 2016-03-20 |
| JP2015509111A (ja) | 2015-03-26 |
| CN104302315A (zh) | 2015-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201503927B (en) | Immunogenic composition | |
| SG11201404447WA (en) | Immunogenic composition | |
| PL2647387T3 (pl) | Kompozycja szczepionki | |
| SG11201500412TA (en) | Vaccine compositions | |
| IL238079A0 (en) | Immunogenic preparation | |
| GB201200707D0 (en) | Composition | |
| SG10201702685WA (en) | Immunogenic composition | |
| GB201223342D0 (en) | Immunogenic composition | |
| PL3564378T3 (pl) | Kompozycja immunogenna | |
| EP2878295A4 (en) | COMPOSITION | |
| GB201218660D0 (en) | Immunogenic composition | |
| EP2910537A4 (en) | AGENT COMPOSITION GENERATING GAS | |
| GB201204968D0 (en) | Immunogenic composition | |
| GB201204851D0 (en) | Immunogenic composition | |
| GB201202695D0 (en) | Composition |